- Home
- Applications
- drug platform candidate
Drug Platform Candidate Product Applications
4 applications found
Several of the Navigo-created, ready-to-go Affilin molecules against solid tumor targets are currently developed as protein-drug conjugates (PDCs), by combining them to a half-life extending module and an engineered toxin-carrying moiety. Compared to notoriously difficult-to-produce and inhomogeneous Antibody-Drug Conjugates (ADCs), Affilin®-based PDCs have clear advantages. They are easily assembled from a specificity-conferring Affilin®, a half-life extending module and a toxin-carrying moiety. Each of ...
ByNavigo Proteins GmbH based in Halle, GERMANY
Increase clinical translation with Organ-Chips for ADME-Tox assessments. Accurate ADME-Tox profiling of preclinical drug candidates remains a challenge. Preclinical ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) studies are pivotal to predicting human response. However, approximately 30% of drugs fail during human clinical trials due to adverse reactions despite promising preclinical study results, and another 60% fail due to lack of efficacy. As companies broaden the modality toolbox ...
ByEmulate based in Boston, MASSACHUSETTS (USA)
In many therapeutic areas, current treatments involve significant side effects. Combining drug compounds with affinity agents that target specific cell surface receptors can dramatically reduce off-target effects and improve treatment effectiveness. In several studies, aptamer-mediated drug delivery has reduced toxicity and improved drug performance. ...
ByBase Pair Biotechnologies, Inc. based in Pearland, TEXAS (USA)
More than 5 million people in the United States and an estimated 50 million people worldwide are living with Alzheimer’s disease. More than 10 million people worldwide are living with Parkinson’s. Brain tumors and tumors of the central nervous system are the most common form of cancer in children under 19 and the leading cause of cancer-related deaths in children under 14 in the U.S. While antibody drugs have made great strides in cancer therapies, crossing the blood-brain barrier (BBB) and ...
ByBase Pair Biotechnologies, Inc. based in Pearland, TEXAS (USA)